HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Irbesartan/Hydrochlorothiazide : in moderate to severe hypertension.

Abstract
* The fixed-dose combination of irbesartan/hydrochlorothiazide (HCTZ) is approved in the US for use as initial therapy in patients who are likely to need multiple agents to achieve their blood pressure (BP) goals. * In a 12-week, randomized, double-blind, multicentre trial in 538 patients with moderate hypertension that was untreated or uncontrolled by monotherapy, the mean reduction from baseline in seated systolic BP (SeSBP) at week 8 (primary endpoint) was significantly greater with irbesartan/HCTZ than with either irbesartan or HCTZ as monotherapy. * In addition, the proportion of patients with moderate hypertension achieving controlled BP (SeSBP < 140 mmHg/seated diastolic BP [SeDBP] < 90 mmHg) at 12 weeks was significantly greater with irbesartan/HCTZ combination therapy than with irbesartan or HCTZ monotherapy. * In a 7-week, randomized, double-blind, multicentre trial in 697 patients with severe hypertension that was untreated or uncontrolled by monotherapy, a significantly greater proportion achieved a trough SeDBP of < 90 mmHg following 5 weeks of combination therapy with irbesartan/HCTZ compared with irbesartan monotherapy (primary endpoint). * Furthermore, the proportion of patients with severe hypertension achieving controlled BP of < 140/90 mmHg was significantly greater at all timepoints of the trial compared with irbesartan monotherapy. * Irbesartan/HCTZ combination therapy had a similar tolerability profile to irbesartan and HCTZ monotherapy. Most adverse events were of mild to moderate intensity.
AuthorsJamie D Croxtall, Gillian M Keating
JournalDrugs (Drugs) Vol. 68 Issue 10 Pg. 1465-72 ( 2008) ISSN: 0012-6667 [Print] New Zealand
PMID18578561 (Publication Type: Journal Article)
Chemical References
  • Antihypertensive Agents
  • Biphenyl Compounds
  • Drug Combinations
  • Tetrazoles
  • Hydrochlorothiazide
  • irbesartan
Topics
  • Antihypertensive Agents (administration & dosage, adverse effects, pharmacokinetics)
  • Biphenyl Compounds (administration & dosage, pharmacokinetics, therapeutic use)
  • Clinical Trials as Topic
  • Drug Combinations
  • Humans
  • Hydrochlorothiazide (administration & dosage, adverse effects, pharmacokinetics)
  • Hypertension (drug therapy)
  • Severity of Illness Index
  • Tetrazoles (administration & dosage, pharmacokinetics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: